PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame.

Abstract The Immunization Systems Management Group (IMG) was established as a time-limited entity, responsible for the management and coordination of Objective 2 of the Polio Eradication and Endgame Strategic Plan. This objective called for the introduction of at least 1 dose of inactivated polio vaccine (IPV) into the routine immunization programs of all countries using oral polio vaccine (OPV) only. Despite global vaccine shortages, which limited countries' abilities to access IPV in a timely manner, 105 of 126 countries using OPV only introduced IPV within a 2.5-year period, making it the fastest rollout of a new vaccine in history. This achievement can be attributed to several factors, including the coordination work of the IMG; high-level engagement and advocacy across partners; the strong foundations of the Expanded Programme on Immunization at all levels; Gavi, the Vaccine Alliance's vaccine introduction experiences and mechanisms; innovative approaches; and proactive communications. In many ways, the IMG's work on IPV introduction can serve as a model for other vaccine introductions, especially in an accelerated context.
PMID
Related Publications

Exceptional Financial Support for Introduction of Inactivated Polio Vaccine in Middle-Income Countries.

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region.

Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region.

Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.

Polio Endgame: Lessons Learned From the Immunization Systems Management Group.

Authors

Mayor MeshTerms

Disease Eradication

Global Health

Immunization Programs

Poliovirus Vaccine, Inactivated

Keywords

IPV

endgame

inactivated polio vaccine

oral polio vaccine

polio

polio eradication

routine immunization

vaccine introduction

vaccine shortage

vaccine supply

vaccines

Journal Title the journal of infectious diseases
Publication Year Start




PMID- 28838203
OWN - NLM
STAT- MEDLINE
DA  - 20170825
DCOM- 20170911
LR  - 20170911
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 216
IP  - suppl_1
DP  - 2017 Jul 01
TI  - Lessons Learned From Managing the Planning and Implementation of Inactivated
      Polio Vaccine Introduction in Support of the Polio Endgame.
PG  - S15-S23
LID - 10.1093/infdis/jix185 [doi]
AB  - The Immunization Systems Management Group (IMG) was established as a time-limited
      entity, responsible for the management and coordination of Objective 2 of the
      Polio Eradication and Endgame Strategic Plan. This objective called for the
      introduction of at least 1 dose of inactivated polio vaccine (IPV) into the
      routine immunization programs of all countries using oral polio vaccine (OPV)
      only. Despite global vaccine shortages, which limited countries' abilities to
      access IPV in a timely manner, 105 of 126 countries using OPV only introduced IPV
      within a 2.5-year period, making it the fastest rollout of a new vaccine in
      history. This achievement can be attributed to several factors, including the
      coordination work of the IMG; high-level engagement and advocacy across partners;
      the strong foundations of the Expanded Programme on Immunization at all levels;
      Gavi, the Vaccine Alliance's vaccine introduction experiences and mechanisms;
      innovative approaches; and proactive communications. In many ways, the IMG's work
      on IPV introduction can serve as a model for other vaccine introductions,
      especially in an accelerated context.
CI  - (c) The Author 2017. Published by Oxford University Press for the Infectious
      Diseases Society of America.
FAU - Zipursky, Simona
AU  - Zipursky S
AD  - World Health Organization, Geneva, Switzerland.
FAU - Patel, Manish
AU  - Patel M
AD  - Task Force for Global Health, Atlanta, Georgia.
FAU - Farrell, Margaret
AU  - Farrell M
AD  - Programme Division, United Nations Children's Fund, New York, New York.
FAU - Gonzalez, Alejandro Ramirez
AU  - Gonzalez AR
AD  - World Health Organization, Geneva, Switzerland.
FAU - Kachra, Tasleem
AU  - Kachra T
AD  - Bill & Melinda Gates Foundation, Seattle, Washington.
FAU - Folly, Yann
AU  - Folly Y
AD  - Gavi, the Vaccine Alliance, Geneva, Switzerland.
FAU - Kurji, Feyrouz
AU  - Kurji F
AD  - FDK Consulting, Kirkland, Washington.
FAU - Veira, Chantal Laroche
AU  - Veira CL
AD  - Task Force for Global Health, Atlanta, Georgia.
FAU - Wootton, Emily
AU  - Wootton E
AD  - Gavi, the Vaccine Alliance, Geneva, Switzerland.
FAU - Hampton, Lee M
AU  - Hampton LM
AD  - Centers for Disease Control and Prevention, Atlanta, Georgia.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Poliovirus Vaccine, Inactivated)
RN  - 0 (Poliovirus Vaccine, Oral)
SB  - AIM
SB  - IM
MH  - *Disease Eradication/methods/organization & administration
MH  - *Global Health
MH  - Humans
MH  - *Immunization Programs/methods/organization & administration
MH  - Poliomyelitis/*prevention & control
MH  - *Poliovirus Vaccine, Inactivated/administration & dosage/therapeutic use
MH  - Poliovirus Vaccine, Oral
OTO - NOTNLM
OT  - IPV
OT  - endgame
OT  - inactivated polio vaccine
OT  - oral polio vaccine
OT  - polio
OT  - polio eradication
OT  - routine immunization
OT  - vaccine introduction
OT  - vaccine shortage
OT  - vaccine supply
OT  - vaccines
EDAT- 2017/08/26 06:00
MHDA- 2017/09/12 06:00
CRDT- 2017/08/26 06:00
AID - 3935081 [pii]
AID - 10.1093/infdis/jix185 [doi]
PST - ppublish
SO  - J Infect Dis. 2017 Jul 1;216(suppl_1):S15-S23. doi: 10.1093/infdis/jix185.